LRRK2 and Parkinson disease: Additional studies are required to determine whether sub-antibiotic doses of doxycycline are safe for PD patients during prolonged treatments, as well as whether combination therapy with doxycycline and existing treatments for PD (e.g., LRRK2 kinase inhibitors) represent potential therapeutic approaches.